A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

• Published in: British journal of dermatology (1951) Vol. 169; no. 1; pp. 137 - 145
• Main Authors: Ports, W.C., Khan, S., Lan, S., Lamba, M., Bolduc, C., Bissonnette, R., Papp, K.
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell Publishing Ltd 01.07.2013; Wiley-Blackwell
• Subjects: Administration, Cutaneous; Adult; Aged; Biological and medical sciences; Chronic Disease; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Dermatologic Agents - pharmacokinetics; Dermatology; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Medical sciences; Middle Aged; Ointments; Original; Piperidines - administration & dosage; Piperidines - adverse effects; Piperidines - pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Psoriasis - drug therapy; Psoriasis. Parapsoriasis. Lichen; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrroles - administration & dosage; Pyrroles - adverse effects; Pyrroles - pharmacokinetics; Treatment Outcome; Young Adult; Local administration; Skin disease; Chronic; Randomization; Phase; Treatment; Psoriasis; Dermatology; Tyrosine kinase inhibitor; Clinical trial; Safety

Summary Background Tofacitinib (CP‐690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory diseases including psoriasis. Objectives This phase 2a study aimed to assess the efficacy, systemic safety, local tolerability and systemic ph...